Dramatic licence

By Jenny Bryan2000-04-27T00:00:00

Cancer patients are not benefiting from the large number of new drugs available because purchasers will be reluctant to fund them until they have the NICE seal of approval. Jenny Bryan squares the circle

You need to be signed in to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All of HSJ.co.uk and our HSJ mobile app
News and insight on all areas of public funded healthcare
Expert commentary, insight and analysis from industry leaders
9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

to HSJ

Sign into your account here